

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

INSIDER INFORMATION

ACHIEVING MAJOR MILESTONES IN THE COLLABORATION WITH JANSSEN BIOTECH, INC.

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the inside information announcements of the Company dated 22 December 2017, 17 December 2018, 28 July 2019 and 28 January 2020 (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

The Board is pleased to announce that, Legend Biotech Corporation (“**Legend**”), a non-wholly owned subsidiary of the Company, announced the initiation of a rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for ciltacabtagene autoleucel (cilta-cel) (the “**Submission**”), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy, for the treatment of adults with relapsed and/or refractory multiple myeloma.

The Submission is based on results from the pivotal Phase 1b/2 CARTITUDE-1 study which evaluated the efficacy and safety of cilta-cel in the treatment of patients with relapsed and/or refractory multiple myeloma. The latest data from the study were recently presented (Abstract #177) at the 62nd American Society of Hematology Annual Meeting. For details of the latest data from the study, please refer to the announcement made by the Company on 6 December 2020.

The Board is also pleased to announce that, according to the terms and conditions of the Agreement (as defined in the announcement of the Company dated 22 December 2017) entered into between Legend and Janssen Biotech, Inc. (“**Janssen**”), the fifth milestone relating to the clinical development of cilta-cel has been achieved and Legend is entitled to a milestone payment in the amount of US\$75,000,000 payable by Janssen for the fifth milestone.

To the best knowledge and belief of the Company, Janssen and its ultimate beneficial owners are third parties independent of the Company. The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 21 December 2020

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*